<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532177</url>
  </required_header>
  <id_info>
    <org_study_id>SBU-SBRT-BREAST-NO-SX</org_study_id>
    <nct_id>NCT04532177</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery</brief_title>
  <acronym>SBRT BREAST</acronym>
  <official_title>Prospective Pilot Study of Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective pilot study investigating the safety and efficacy of stereotactic body&#xD;
      radiation therapy (SBRT) as a treatment for breast cancer in patients who do not get surgery.&#xD;
      The study will accrue 15 patients who will be treated to a dose of 40 Gy over the course of 5&#xD;
      fractions in the Stony Brook University Hospital Department of Radiation Oncology. The&#xD;
      subjects will then have a follow up time of 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of acute and late adverse events grade 3 or greater</measure>
    <time_frame>5 years</time_frame>
    <description>Rates of acute and late grade 3 or greater toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial and complete response rate by clinical and radiographic response</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Progression-free survival and overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy (SBRT)</intervention_name>
    <description>fractionated linear accelerator based SBRT to 40 Gy in 5 fractions</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;/= 18&#xD;
&#xD;
          -  Biopsy proven invasive carcinoma of the breast&#xD;
&#xD;
          -  Clinical T1-T4 invasive carcinoma&#xD;
&#xD;
          -  Cancer is deemed unresectable with no possibility of future resection or the patient&#xD;
             is a poor surgical candidate as determined following evaluation by a surgeon.&#xD;
&#xD;
          -  Women who are not post-menopausal should have a negative urine or serum pregnancy&#xD;
             test. Women of childbearing potential must agree to adequate contraception for the&#xD;
             duration of study participation.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Patient is to be treated at Stony Brook University Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with a known pregnancy, positive serum pregnancy test, or currently&#xD;
             breastfeeding as well as women of childbearing potential unwilling or unable to use an&#xD;
             acceptable method of birth control (including abstinence or barrier method of birth&#xD;
             control) to avoid pregnancy for the duration of the study. Should a woman become&#xD;
             pregnant or suspect she is pregnant while participating in this study, she should&#xD;
             inform her treating physician immediately.&#xD;
&#xD;
          -  Breast implant in the breast to be treated with SBRT&#xD;
&#xD;
          -  Insufficient breast imaging to judge clinical stage&#xD;
&#xD;
          -  Inability to receive study treatment planning and treatment secondary to body habitus&#xD;
&#xD;
          -  Inability to understand or unwillingness to sign a written consent document&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Children (&lt; 18 years of age)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness or social situation that would limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander M Stessin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pushpa Talanki</last_name>
    <phone>631-638-0815</phone>
    <email>pushpa.talanki@stonybrookmedicine.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Roberson, MD</last_name>
    <phone>631-444-2200</phone>
    <email>John.Roberson@stonybrookmedicine.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander M Stessin, MD</last_name>
      <phone>631-444-2200</phone>
      <email>alexander.stessin@stonybrookmedicine.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caterina Vacchi-Suzzi, PhD</last_name>
      <phone>631-216-2993</phone>
      <email>caterina.vacchi-suzzi@stonybrookmedicine.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Alexander Stessin</investigator_full_name>
    <investigator_title>Clinical Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

